Congress mandates free breast cancer screening for high-risk women

What it does

The Find It Early Act mandates that health insurance plans (private, Medicare, Medicaid, TRICARE, and VA) cover advanced breast cancer screening and diagnostic imaging—including mammograms, ultrasounds, MRI, and molecular imaging—with zero cost-sharing for women at elevated risk (based on age, family history, race, ethnicity, or dense breast tissue) or those whose doctors recommend screening. The law applies to all major insurance programs and takes effect January 1, 2026, ensuring that cost is not a barrier to early detection for high-risk populations.

Why we flagged it

The bill's core function is to expand insurance coverage for breast cancer screening across all major federal and private insurance programs, with zero cost-sharing for high-risk populations. This is a preventive health mandate, not a tax provision, regulatory carve-out, or commemorative measure.

What the text implies

• Imaging technology companies (ultrasound, MRI, molecular imaging manufacturers) may see increased demand as more women access advanced screening modalities beyond standard mammography.
• State Medicaid programs face new mandatory coverage requirements and may need to adjust budgets or seek federal matching funds; states with tight budgets may experience fiscal pressure.
• The bill defines eligibility using external clinical guidelines (American College of Radiology, National Comprehensive Cancer Network) rather than statutory criteria, meaning coverage scope can shift if those organizations update recommendations without legislative action.
• Unlimited frequency of screening (no limitation applied) for high-risk individuals may increase overall imaging volume and associated healthcare costs, though early detection may offset downstream treatment expenses.

Who it affects

Ordinary people—particularly women at higher breast cancer risk—gain direct access to advanced screening without out-of-pocket costs, removing a financial barrier to early detection. The law covers multiple insurance pathways (private, Medicare, Medicaid, military, VA), ensuring broad population reach. Early detection saves lives and reduces treatment costs downstream.

Who stands to gain

• Medical imaging equipment manufacturers (ultrasound, MRI, molecular breast imaging)
• Diagnostic imaging centers and radiology practices
• Healthcare IT vendors supporting imaging workflows

Named in the bill

American College of Radiology, National Comprehensive Cancer Network, Breast Imaging Reporting and Data System, Centers for Medicare & Medicaid Services, Department of Veterans Affairs, Department of Defense (TRICARE), State Medicaid programs

Where it stands

10 cosponsors: 7 Democrats, 3 Republicans.

• Apr 10, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Apr 10, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 9 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,430,000 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Amy Klobuchar, the sponsor, reported $116,500 in PAC receipts in the 2026 cycle.

• GE Healthcare Technologies Inc. — $730,000 on 2 filings
• American College of Surgeons — $440,000 on 2 filings
• Hadassah, the Women's Zionist Organization of America, Inc. — $120,000 on 2 filings
• Society of Nuclear Medicine and Molecular Imaging — $80,000 on 1 filing
• American College of Surgeons Professional Association — $60,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.